Online Treatment Tool for Patients: Key Information You Need to Know About Your HER2-Positive Early Breast Cancer Diagnosis

Download this PDF consultation checklist with useful questions for your oncologist about your new HER2-positive early breast cancer diagnosis. You can then enter the specific information about your cancer into our interactive treatment tool by answering a series of multiple choice questions to see treatment options chosen by 5 breast cancer experts.
Format: Adobe Acrobat (.pdf)
File Size: 137 KB
Released: March 19, 2019


Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Grace Logo
This activity is supported by an educational grant from

Related Content

Download these expert-selected slides on treatments for early and later-stage relapsed/refractory multiple myeloma

Sagar Lonial, MD Thomas G. Martin, MD Released: October 6, 2022

A focused text activity providing an expert review of the evolution in CLL treatment during the past several years, from Clinical Care Options (CCO)

Nichole Fisher Headshot Nichole Fisher, RN, BSN Nicole Lamanna, MD Anthony Perissinotti, PharmD, BCOP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 6, 2022 Expired: October 5, 2023

Downloadable slideset on current best practices and standard treatments for the management of CLL/SLL in the first-line and relapsed settings, from Clinical Care Options (CCO).

Farrukh T. Awan, MD Nicole Lamanna, MD Released: October 5, 2022

Experts answer audience questions from a live symposium at THSNA 2022 on emerging strategies for treatment of hemophilia A and B, from Clinical Care Options (CCO)

Glaivy Batsuli, MD Allison Wheeler, MD, MSCI Guy A. Young, MD Released: October 4, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings